One Watertown, Mass.-based biotech is working to capitalize on growing momentum for cell and gene therapies — and it seems to have found its opening.
The company is working on a technology that will squeeze cells to open up tiny pores in their membranes to deliver gene therapies or medicines straight into the cell. And SQZ has had a busy fall. It closed a $72 million series C fundraising round in August. Even more recently, the company extended a partnership with Roche that could bring in more than $1.3 billion, if SQZ and Roche can get some products to market.
Its uplifting to read these stories. Once in a while though, it would be nice to see some failure stories of academic science entrepreneurship (as we know there are many) and the deeper reasons behind them. Probably another reason why everyone can’t take the risk of being an entrepreneur or working in a biotech start up that is starting from scratch.
Comments are closed.